Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Tavolimab (MEDI0562) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 1052PD).
|DrugClasses||OX40 Antibody 10|
|CAS Registry Number||1635395-25-3|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Durvalumab + Tavolimab||Durvalumab Tavolimab||0||1|
|Tavolimab + Tremelimumab||Tavolimab Tremelimumab||0||2|